ArticlemAbs2016
The European antibody network's practical guide to finding and validating suitable antibodies for research.
Article in mAbs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 61 citations in OpenAlex.
- Optimized monoclonal antibody panel for accurate immunohistochemical detection of haematopoietic cell populations in animal species.BMC veterinary research · 2026Article
- Organotellurium Probes Enable One-step Single-cell Analysis of Post-translational Modification.Journal of the American Chemical Society · 2026Article
- January in focus in HCB: antibody validation.Histochemistry and cell biology · 2026Article
- Reducing Bias in Mass Cytometry Data through Corrections for Spillover and Nonspecific Binding.Analytical chemistry · 2026Article
- Article
- Article
- Data-driven evaluation of suitable immunogens for improved antibody selection.Protein science : a publication of the Protein Society · 2025Article
- Increased expression of CXCL10 and CCL3 salivary gland chemokines in primary Sjögren's syndrome detected and systematically quantified using RNAscope®in situ hybridization.Clinical and experimental immunology · 2025Article
- Decision Tree for Protein Biomarker Selection for Clinical Applications.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Antibody characterization is critical to enhance reproducibility in biomedical research.eLife · 2024Review
- Evaluation of Antibodies for Vascular Smooth Muscle Cell Characterization.Stem cell and regenerative medicine (Wilmington, Del.) · 2024Article
- A reverse phase protein array based phospho-antibody characterization approach and its applicability for clinical derived tissue specimens.Scientific reports · 2022Article
- Bioinformatics tools and data resources for assay development of fluid protein biomarkers.Biomarker research · 2022Review
- The Anti-Glucocorticoid Receptor Antibody Clone 5E4: Raising Awareness of Unspecific Antibody Binding.International journal of molecular sciences · 2022Article
- MALDI-TOF-MS-Based Identification of Monoclonal Murine Anti-SARS-CoV-2 Antibodies within One Hour.Antibodies (Basel, Switzerland) · 2022Article
- Article
- Development of Antibody and Nanobody Tools for P2X7.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Double Labeling Fluorescent Immunocytochemistry.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Rodent Models of Congenital Cytomegalovirus Infection.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck.Cell death & disease · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 13 institutions in 8 countries.
Funding
Abstract
Antibodies are widely exploited as research/diagnostic tools and therapeutics. Despite providing exciting research opportunities, the multitude of available antibodies also offers a bewildering array of choice. Importantly, not all companies comply with the highest standards, and thus many reagents fail basic validation tests. The responsibility for antibodies being fit for purpose rests, surprisingly, with their user. This paper condenses the extensive experience of the European Monoclonal Antibody Network to help researchers identify antibodies specific for their target antigen. A stepwise strategy is provided for prioritising antibodies and making informed decisions regarding further essential validation requirements. Web-based antibody validation guides provide practical approaches for testing antibody activity and specificity. We aim to enable researchers with little or no prior experience of antibody characterization to understand how to determine the suitability of their antibody for its intended purpose, enabling both time and cost effective generation of high quality antibody-based data fit for publication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.